Clinical trial • Phase I • Oncology
Cetuximab for Glioblastoma
Phase I trial of Cetuximab for Glioblastoma. 21 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Glioblastoma
- Trial Stage
- Phase I
- Drug Modality
- Monoclonal antibody|Small molecule
Key dates
- Initial CTIS Submission Date
- 22-08-2024
- First CTIS Authorization Date
- 03-09-2024
Trial design
Phase I trial across 1 site in Netherlands.
- Target Sample Size
- 21
Recruitment
- Planned Sample Size
- 21
- Recruitment Window Months
- 27
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 21
Netherlands
- Earliest CTIS Part Ii Submission Date
- 22-08-2024
- Latest Decision Or Authorization Date
- 03-09-2024
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 21
Sites
- Site Name
- UMCG
- Department Name
- Neurosurgery
- Contact Person Name
- Rob Groen
- Contact Person Email
- r.j.m.groen@umcg.nl
- Number Of Participants
- 21
Sponsor
Primary sponsor
- Full Name
- Universitair Medisch Centrum Groningen
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Netherlands
Investigational products
- Investigational Product Name
- Cetuximab-IRDye800CW
- Active Substance
- Cetuximab
- Modality
- Monoclonal antibody
- Investigational Product Name
- 5-ALA
- Active Substance
- 5-aminolevulinic acid (5-ALA)
- Modality
- Small molecule
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.